Guselkumab: the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults.

Guselkumab is a subcutaneously administered human monoclonal antibody, selectively blocking IL-23 through binding to its p19 subunit. It was initially approved for the treatment of patients with mo...